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Introduction
Originat ing  f rom the  inters t i t i a l  ce l l s  o f  Ca ja l , 
gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal neoplasms of the gastrointestinal 
(GI) tract (1,2). Subendothelial in location, GISTs typically 
present in the seventh decade of life and can arise anywhere 
along the GI tract, most commonly in the stomach. 
The discovery of the KIT and platelet derived growth 
factor receptor alpha (PDGFRA) tyrosine-kinase gain of 
function mutations, which result in continuous activation 
and signaling, dramatically altered the understanding and 
treatment of GISTs (3,4). Approximately 90% of GISTs 
are driven by gain-of-function mutations in one of the 
two type-III tyrosine kinase receptors. Although resection 
remains a principle therapy, tyrosine-kinase inhibitors have 
revolutionized the treatment of advanced and recurrent 
GISTs, allowing many patients with advanced disease to 
live many years and in some instances, obtain complete 
remission (5-8).
Wild-type gastrointestinal stromal tumors (WT-
GISTs) are defined as GISTs that lack the gain-of-function 
mutations in KIT and PDGFRA (9). Due to the different 
molecular drivers and the distinct tumor biology and 
behavior of these wild-type neoplasms, a different approach 
to treatment may be required when addressing these distinct 
GISTs.
Epidemiology of WT-GIST
Regardless of subtype, the incidence of all GISTs is 
approximately 14–20 per million population (1). The 
incidence of WT-GIST is as much as 10% of all GISTs (10). 
Patients with WT-GISTs usually present at a much younger 
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age. GISTs arising in younger patients are much more 
commonly associated with the wild-type variant. In patients 
under 23 years of age, 85% of GISTs are WT (4,11).
Molecular characteristics of WT-GIST
The majority of GISTs have mutations in the proto-
oncogenes KIT or PDGFRA. Mutations in these tyrosine 
kinase receptors result in ligand independent kinase 
activation, resulting in cellular proliferation and oncogenesis 
(1,3,4,9). Wild-type GIST variants are negative for 
mutations in KIT and PDGFRA. Consequently, these rare 
wild-type GISTs are generally resistant to tyrosine kinase 
inhibitors (i.e., imatinib and sunitinib) currently used in the 
treatment of the more common variety of GISTs (1). Thus, 
an understanding of the molecular characteristics of these 
wild-type GISTs is important for making clinical decisions 
and for the future development of targeted therapeutic 
agents against these rare tumors.
Recent studies demonstrate that WT-GISTs are an 
entity with multiple subtypes. Of these subtypes, the 
succinate dehydrogenase (SDH) deficiency variant is the 
most common. The SDH-ubiquinone complex II is an 
enzyme complex found in the Krebs cycle and the electron 
transport chain. Loss of function of SDH is thought to play 
a central role in the pathogenesis of many WT-GISTs. It 
is postulated that SDH deficiency may lead to activation 
of insulin-like growth factor 1-receptor (IGF1R) signaling 
and results in oncogenesis. These SDH deficient GISTs 
arise exclusively in the stomach as multiple lesions. They 
also have a predilection for young female patients and 
are responsible for over half of gastric GISTs in patients 
under 40 years (1,12-15). Mutations of SDH are not solely 
exclusive to GIST pathogenesis and have been associated 
with other tumors such as malignant pheochromocytoma 
and renal cell carcinoma (13).
The majority of SDH deficient WT-GISTs are due 
to germline or somatic mutation in the SDH complex, 
specifically in genes coding for its subunits: SDHA, 
SDHB, SDHC, or SDHD. SDHA and SDHB code for 
subunits involved in the enzymatic activity of SDH, while 
SDHC and SDHD code for the subunits which anchor 
the SDH complex to the inner mitochondrial membrane. 
Mutations in all subunits have been implicated in WT-
GIST formation; however, mutations in the SDHA subunit 
are most common. SDH deficiency can also be expressed 
without inactivating mutations of the gene itself, but 
through hypermethylation. Specifically, it has been found 
that methylation at the SDHC promoter leads to silencing 
of gene expression (16,17).
The remaining WT-GISTs are classified as SDH-
competent. These tumors have demographic features similar 
to c-KIT/PDGFRA mutant tumors with the exception of 
their propensity to occur in the small bowel (17). SDH-
competent WT-GISTs may be associated with other 
mutations such as Neurofibromatosis type-1 (NF1), BRAF 
V600E (BRAF), RAS, or quadruple WT GISTs, which lack 
abnormalities in c-KIT, PDGFRA, SDH and RAS (17-22). 
Syndromic associations of WT-GIST
In addition to occurring sporadically, WT-GISTs may be 
the result of an associated syndrome. GISTs are a well-
established manifestation of neurofibromatosis type-I (NF1), 
with up to 25% of patients with NF1 developing a GIST 
over their lifetime (23,24). Additionally, these tend to be 
WT-GISTs (25,26).
Carney-Stratakis syndrome (CSS) is characterized by 
paragangliomas and GISTs. Carney triad (CT) describes the 
association of paragangliomas with GISTs and pulmonary 
chondromas. Both CSS and CT have been associated with 
SDH-deficient WT-GISTs (14).
Familial GIST syndrome is a rare hereditary disorder 
characterized by germline gain-of-function KIT mutations 
and less commonly PDGFRA mutations. These are not 
associated with WT-GIST tumors (1).
Diagnosis
Initial diagnosis and treatment is similar for all GISTs 
and is outlined in Figure 1. Imaging, biopsy, pathologic 
examination and molecular analysis are all part of the 
diagnostic work up. 
Imaging
The diagnosis of all GIST can often be suspected based on 
imaging features. Computed tomography (CT) scan of the 
abdomen and pelvis showing a heterogeneously, vascularly 
enhancing exophytic mass emanating from the GI tract is 
the predominant pattern seen with GIST (27,28). 
Endoscopic ultrasound and biopsy
Diagnosis of an abdominal mass suspicious for GIST 
can reasonably be treated with surgery directly without 
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additional procedures. If the diagnosis remains unclear, 
however, endoscopic or endoscopic ultrasound-directed 
fine needle aspiration may be performed (29). Percutaneous 
biopsy should be avoided due to the risk of seeding the 
biopsy tract with cancerous cells. In the setting of large 
tumors PET scanning may also be considered to better 
stage patients and to monitor the metabolic activity of the 
tumor.
Pathologic analysis
Initial pathologic analysis must include the determination of 
the dimensions of the tumor and histologic analysis focusing 
specifically on mitotic rate. Size and mitotic rate are the 
main factors in risk stratification (Table 1). Testing for the 
presence of c-KIT and PDGFRA mutations is a standard 
part of the initial analysis for any GIST (29).
Molecular subtyping
Tumors lacking c-KIT and PDGFRA mutations should be 
approached in a step wise fashion starting with testing for 
SDH status (Figure 2) (31). Immunohistochemical staining 
with observed loss of the ubiquitously expressed SDHB 
has proven to be an accurate and cost-efficient diagnostic 
marker for SDH deficiency (15,17,32,33). Patients with 
SDH competent tumors should be tested for mutations in 
NF1 and BRAF as these have been identified to be present 
in SDH competent WT-GISTs (34).
Patients with SDH deficient WT-GISTs should undergo 
Figure 1 Diagnostic algorithm for WT-GIST; WT-GIST, wild-type gastrointestinal stromal tumor.
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tumor and germline sequencing of SDH because those 
with SDHX germline mutations are at increased risk for 
developing paraganglioma, pheochromocytoma, and other 
tumors (35). Routine screening with total body magnetic 
resonance imaging (MRI), urine metanephrines, and/
or plasma catecholamines along with referral to a genetic 
counselor should also be strongly considered (36).
Treatment for WT-GIST
In our current armamentarium against GISTs, surgical 
management remains standard and is the only option that 
offers the potential for cure in patients with resectable 
tumors (18). In about 60% of individuals, surgery can 
offer cure (27). GISTs are resistant to standard cytotoxic 
chemotherapeutics available (11). In patients with 
locally advanced disease, metastatic disease or recurrent 
disease, tyrosine kinase inhibitors, like imatinib mesylate, 
have offered patients a treatment option with studies 
demonstrating excellent response (9). However, WT-
GISTs in particular remain a challenge as they are generally 
resistance to imatinib (31).
While treatment strategies for WT-GISTs are not 
clearly established. The NIH Pediatric and Wild-Type 
GIST clinic data demonstrated no improvement in event-
free survival with extensive or serial resections and proposed 
surgical therapy to be reserved for initial resection and only 
repeat resections to address palliation of symptoms such as 
obstruction or bleeding (37). Nonetheless, surgical resection 
remains a critical component, perhaps the key component, 
in the overall treatment of WT-GIST as it provides the 
only chance for cure and can optimize palliation (38-40).
Although type-III tyrosine kinase receptor therapy 
Table 1 Risk stratification for GIST
Risk of progression Size (cm) Mitotic count (per 50 HPF)
Very low <2 <5
Low 2–5 <5
Intermediate <5 6–10
5–10 <5
High >5 >5
>10 Any mitotic count
Adapted with permission from Trifan et al. (30). HPF, high power 
fields; GIST, gastrointestinal stromal tumor.
Figure 2 Treatment algorithm for WT-GIST. WT-GIST, wild-type gastrointestinal stromal tumor.
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has proven ineffective, there may be a role for alternative 
adjunct treatments in WT-GIST. Pazopanib, a vascular 
endothelial growth factor receptor (VEGFR) inhibitor has 
recently been shown to improve progression-free survival 
in patients with advanced GIST resistant to imatinib and 
sunitinib (41). Additionally, the BRAF inhibitor dabrafenib, 
has demonstrated prolonged antitumor activity in V600E 
BRAF-mutated GIST (42). MEK inhibition has similarly 
been shown to reduce the growth of tumors in patients with 
NF-1 (43). Lastly, inhibition of insulin-like growth factor 
receptor 1 has led to cytotoxicity and induced apoptosis 
in patients with WT-GIST (44). For all of the adjunctive 
therapies additional trials will be needed. 
Conclusions
In summary, WT-GISTs represent a special subset of GIST 
that require specialized treatment strategies based on their 
unique biological characteristics. While surgical resection 
remains the cornerstone of treatment for resectable tumors 
and an option for symptomatic tumors, testing for SDH 
competence is indicated for all GISTs that lack c-KIT and 
PDGFRA mutations. Further testing and treatment must 
be individualized based on SDH competence and include 
testing for SDHX somatic and germline mutations, NF-1, 
V600E BRAF, RAS, and other genes. While these 
tumors are not responsive to imatinib, initiation of novel 
therapeutic agents based on additional testing may prove to 
be beneficial. WT-GIST still, however, represents a unique 
clinical entity for which additional research needs to be 
undertaken to establish the best therapeutic approach.
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